seems always to be the woman. This probably relates to the X-chromosomal localization of DCX.
Our study has important implications for genetic counseling of families with SBH/XLIS patients. Owing to the high rate of mosaicism and based on the possibility of incomplete or nonpenetrance of symptoms (Family C and references 5 and 9), we suggest that parents of affected men or affected women should be analyzed for mutations in the DCX gene. To limit the number of false-negative results obtained by analyzing lymphocyte DNA, we suggest including DNA isolated from ectodermal cells (skin biopsy), hair roots, 6 or corticospinal fluid in the analysis. The genetic analysis of patients should take the high incidence of somatic mutations into account. In the case of an early pregnancy in a SBH/XLIS family, prenatal diagnosis of the DCX gene should be considered. Refractory status epilepticus (RSE) (seizure duration Ն 60 minutes) has a Ͼ30% mortality, 10 times that of status epilepticus (SE) successfully terminated earlier, underscoring the need for effective intervention. 1 The standard definition of SE is 30 minutes of continuous seizure activity or discrete seizures without recovery of consciousness between. However, determining the duration of SE is not always possible because seizure onset may not have been observed. Thus, therapy to terminate SE should be initiated as rapidly and safely as possible, and administration of antiepileptic drugs should begin whenever a seizure has lasted from 5 to 10 minutes.
Topiramate is an anticonvulsant with multiple activities at receptors and ion channels that may be more effective than conventional anticonvulsants in treating RSE. Like phenytoin, topiramate exhibits voltage-sensitive, use-dependent, sodium-channel blockade and may have an additive effect at this site. 2 While topiramate in combination with the use Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the of conventional agents may produce additional usedependent blockade of the sodium channel, its effects at other sites more likely underlie its effectiveness in RSE. Topiramate potentiates GABA inhibition independently of the benzodiazepine site on the GABA A receptor and significantly elevates brain GABA levels. 3, 4 Thus, topiramate may be effective in SE-induced benzodiazepine pharmacoresistance. Another action of topiramate is its ability to antagonize excitatory glutamatergic transmission, providing a mechanism for termination of seizure discharges in RSE. 5 Other actions of topiramate that may contribute to its anticonvulsant effect include inhibiting high-voltage-activated calcium channels 6 and inhibition of carbonic anhydrase activity that may result in pH modulation. 7 Topiramate may have interactions with other anticonvulsants, especially acute effects on protein binding, that potentiate the effects of these agents on RSE. 8, 9 In addition, topiramate has been shown to reduce neuronal injury after prolonged SE and may prevent delayed neuronal death. 10 Because of these multiple mechanisms of action, topiramate was evaluated as an agent to treat RSE. We report our initial experience in using topiramate to treat RSE unresponsive to sequential trials of multiple agents.
Methods. The Greater Richmond Status Epilepticus database is a large, population-based, prospectively collected database of SE patients treated at the Medical College of Virginia Hospitals and all community hospitals in the greater Richmond metropolitan area. For this retrospective case review, the database was searched for patients with RSE treated with topiramate. Case records were reviewed for information regarding patient characteristics, SE etiology, type, duration, and treatment history prior to administration of topiramate.
All patients were unresponsive to a standard treatment protocol of successive IV courses, typically consisting of loading doses of:
Lorazepam ( Topiramate tablets were crushed to a powder and mixed with water. The mixture was allowed to sit for several minutes to avoid clumping and then administered via syringe into a nasogastric tube. Dose escalation and maximum dose were individualized by patient; the maximum topiramate dose was 1,600 mg/d.
Results
. From the database of SE patients, six patients were identified for inclusion in this study. Individual cases are summarized in the table. Seizure activity resolved in all six patients after administration of topiramate, and all were eventually discharged from the hospital. Lethargy was the only reported side effect. Summaries of three cases, representative of the spectrum of SE episodes in this series, appear below.
Case 1: Mixed partial seizures with secondary generalization.
A 39-year-old man with no history of seizures was admitted to the hospital with fever, headache, and altered mental status. During this admission for encephalitis, he developed simple partial seizures with secondary generalization that progressed to SE. After 10 hours of successive treatment with lorazepam, fosphenytoin, and valproate, the patient was put into a pentobarbital coma to control SE and was maintained on pentobarbital and propofol drips. Over the next 2 weeks, any attempt at weaning the pentobarbital resulted in SE recurrence.
On day 30, topiramate was started (100 mg twice daily) and increased to 400 mg four times daily. The patient was successfully weaned from pentobarbital without SE recurrence. He was discharged on phenytoin 300 mg three times daily, phenobarbital 50 mg three times daily, and topiramate 400 mg three times daily.
Case 2: Intermittent complex partial seizures. A 55-year-old woman came to the emergency department because of intermittent complex partial seizures for 4 hours. Seizure history included complex partial seizures with secondary generalization prior to and following a right frontal craniotomy for meningioma resection. Over the next 2 days, intermittent seizures continued. Antiepileptic drug noncompliance was suspected, and lorazepam and valproate were administered. Topiramate 25 mg twice daily was also started. Over the next 12 hours, the patient had approximately 14 seizures per hour. Topiramate and lorazepam were increased, reducing seizure frequency. On day 3, valproate and phenobarbital were continued, lorazepam was decreased, and topiramate was increased to 200 mg twice daily. On day 4, the EEG was slow but showed no seizures. There was improvement over the next 6 days. She was weaned off valproate and lorazepam but continued on topiramate and phenobarbital. On days 11 to 14, she was alert with improved mental status. On day 16, she was discharged on phenobarbital 30 mg twice daily and topiramate 100 mg twice daily. Case 3: Focal motor seizures. A 42-year-old woman with a remote history of astrocytoma with resultant complex partial seizures was hospitalized with respiratory failure secondary to pneumonia. Head CT showed right cerebral middle cerebral artery-posterior cerebral artery watershed strokes. She developed left-sided focal motor SE and was given lorazepam, valproate, and midazolam with temporary seizure control. Two days later, SE recurred and she was given lorazepam, phenytoin, valproate, and fosphenytoin with continued SE. Topamax was started at 100 mg twice daily and increased to 150 mg twice daily with cessation of SE within 24 hours. She was discharged 2 weeks later.
Discussion. In this series of six cases, topiramate effectively terminated RSE in a variety of clinical settings. With several mechanisms of action involving different receptors and ion channels, topiramate would be expected to be effective in SE involving different seizure types. Decreased potential for pharmacoresistance compared with agents with a single mechanism of action would also be anticipated. In this series, topiramate was effective against both generalized convulsive SE and nonconvulsive SE. In several cases, SE control achieved by topiramate averted the need for barbiturate coma, mechanical ventilation, and intensive care admission. Further, in three patients given topiramate as a last resort, after pentobarbital infusion failed, topiramate successfully stopped seizures. Effective daily dosages ranged from 300 mg to 1,600 mg. While additional research is needed to validate these initial observations, topiramate administered nasogastrically appears to be effective in aborting SE, even after a prolonged period of time. A parenteral formulation would allow topiramate to be used more widely in RSE.
